High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's blockbuster momentum.
Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as recent research highlights a split view, with some analysts focusing on strong commercial execution and others stressing that questions around patents and the pipeline may already be reflected in the share price. As you read on, you will see how to interpret these moving...
In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.
Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.
AMD, Linde and Amgen highlight AI demand, contracted growth and drug launches, while supply, margin and pipeline risks remain key factors.
On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]
The pharmaceutical giant's track record in past bear markets is fairly impressive.
Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns. Dittrich, who previou
ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415. The reason, as strange as it sounds, is a drug it does not own. Novartis announced that pelacarsen, an Lp(a)-lowering therapy, missed its Phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON. And since Amgen’s […]
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]
Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Amgen (NASDAQ:AMGN) executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion. Chief Financial Officer Thomas Dittrich, who recently returne
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (NYSE:AZN) received a positive boost after their combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial […]
Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
The latest trading day saw Amgen (AMGN) settling at $382.47, representing a -2.25% change from its previous close.
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
Pre-Market Stock Futures: Futures are trading mixed after a second brutal day, with all major indices finishing lower again. Rising rates, Brent Crude trading above $100, and what appears to be an increase in the Iran attacks in the Persian Gulf were all it took for sellers to keep hitting bids. Once again, the small-cap […]
Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.
On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
Wall Street ended lower as market participants weighed inflation concerns, rising oil prices and interest-rate expectations.
Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.
Here are four highlights of a rocky day in markets Tuesday. Canadian tariffs on U.S. goods kicked in. Oil rose, while stocks fell. Amgen stock shed 10% Howmet Aerospace was the worst performer in the S&P.
Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.
📣 “This is the worst possible outcome for Amgen.” —Barclays analyst Emily Field, on Novartis announcing a disappointing result for its heart disease drug, a disclsoure that also cast doubt on one of Amgen's big drugs.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.